Two days after pharma companies sounded an alarm that their investments were headed out of Europe, Novartis AG has announced ...

The battle to claim the continuous glucose monitor with the longest wear time continues with Dexcom Inc.’s G7 15 Day continuous glucose monitor gaining U.S. FDA clearance on April 10 for adults with ...

Despite a sharp drop in March, total med-tech M&A deal value for the first quarter of 2025 remained significantly higher than last year’s, reaching $10.93 billion compared to $3.63 billion in Q1 2024, ...

Biopharma dealmaking surged in the first quarter of 2025, totaling $66.86 billion, well ahead of the $44.16 billion recorded in the same period last year. March contributed $29.48 billion to the total ...

With a promising IL-36 inhibitor for atopic dermatitis (AD, or eczema) at the phase II stage, Turn Therapeutics Inc. has gained $75 million in post-public commitments and meanwhile is pursuing a ...

The thicket of state-based privacy regulation in the U.S. grows thicker by the day, but Congress seems poised to step in with a bipartisan group that may propose legislation that preempts privacy law.

Cardiovia Ltd.' Viaone epicardial access system received U.S. FDA clearance for treating cardiac arrhythmias. The device provides clinicians with a safe and minimally invasive technology to reach the ...

Shanghai Jemincare Pharmaceuticals Co. Ltd. has identified androgen receptor antagonists reported to be useful for the treatment of cancer, alopecia, acne, hirsutism, polycystic ovary syndrome, ...

Biopharma companies brought in $13.08 billion in financing during the first quarter (Q1) of 2025, marking a significant drop from every quarter of 2024. The number of financings also declined, with ...

LLC have described poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.

Oxford University Innovations Ltd. has synthesized hypoxia-activated proteolysis targeting chimeras (hypoxia-activated PROTACs; HAP-TAC) comprising a hypoxia-activated moiety modified E3 ubiquitin ...

In a roadmap to change animal testing requirements for INDs, the U.S. FDA said its new approach will improve drug safety, hasten the evaluation process, and lower costs for companies and patients.